Audible Premium Plus. $0.99/mo for the first 3 months. Get this deal. Cancel anytime.

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Oct 25 2024
Length: 46 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

Listen for free

View show details

Summary
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPROTACmBC24).

Show more Show less

Show more Show less

What listeners say about Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon